Duyuru • Apr 19
Histogen Inc. Filed for Bankruptcy Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of California on April 18, 2024. The debtor listed its assets in the range of $1 million to $10 million and liabilities in the range of $0.05 million to $0.10 million. The debtor is represented by Eric D. Goldberg of DLA Piper LLP (US) and Armanino LLP as financial advisor as its legal counsel. Duyuru • Jan 05
Histogen Inc. Files Form 15 Histogen Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.0001 per share. Duyuru • Oct 06
Histogen Inc.(OTCPK:HSTO) dropped from NASDAQ Composite Index Histogen, Inc. has been removed from NASDAQ Composite Index . Duyuru • Sep 27
Nasdaq To File A Form 25-NSE with the SEC, To Remove Histogen's Securities from Listing and Registration On September 18, 2023, Histogen Inc. (the “Company”) previously announced that its board of directors (the “Board”) approved a plan of liquidation and dissolution of the Company (the “Plan of Dissolution”), subject to approval by the Company’s stockholders. The Company also announced that it had discontinued all clinical development programs and implemented a reduction in its workforce, including the termination of all employees except for two remaining employees effective September 30, 2023 (“Workforce Reduction”). In light of the Plan of Dissolution and Workforce Reduction, the Company was notified on September 26, 2023 by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Staff’s determination that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101, trading of the Company’s common stock will be suspended from trading at the opening of business on October 5, 2023 unless the Company timely requests a hearing before a Nasdaq Hearings Panel to address the deficiencies and present a plan to regain compliance. The Company does not plan to request a hearing and, therefore, expects that trading in the Company's stock will be suspended upon the opening of business on October 5, 2023. Thereafter, Nasdaq will file a Form 25-NSE with the SEC, which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. Nasdaq has not specified the exact date on which the Form 25-NSE will be filed. Duyuru • Sep 22
Histogen Inc.(NasdaqCM:HSTO) dropped from S&P TMI Index Histogen Inc.(NasdaqCM:HSTO) dropped from S&P TMI Index Duyuru • Sep 19
Histogen Intends to File Certificate of Dissolution, Delist its Shares of Common Stock from The Nasdaq Capital Market Histogen Inc. announced that its board of directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution (‘Plan of Dissolution’) that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including any proceeds from the potential sale of any pipeline assets. In order to reduce costs and in connection with the Plan of Dissolution, the company has discontinued all clinical development programs and reduced its workforce, including the anticipated termination of most employees by the end of September. ‘The Board of Directors and management devoted substantial time and effort in identifying and pursuing various opportunities, but we were unable to complete a transaction that would allow us the potential to enhance stockholder value,’ stated Steven J. Mento, Ph.D., President and Chief Executive Officer of Histogen. On September 18, 2023, Histogen’s board of directors approved the liquidation and dissolution of the company pursuant to the Plan of Dissolution, subject to stockholder approval. The company intends to call a special meeting of its stockholders in the fourth quarter of 2023 to seek approval of the Plan of Dissolution and will file proxy materials with the Securities and Exchange Commission (‘SEC’) as soon as practicable. The Plan of Dissolution contemplates an orderly wind down of Histogen’s business and operations. If Histogen’s stockholders approve the Plan of Dissolution, Histogen intends to file a certificate of dissolution, delist its shares of common stock from The Nasdaq Capital Market, satisfy or resolve its remaining liabilities and obligations, including but not limited to contingent liabilities and claims and costs associated with the dissolution, make reasonable provisions for unknown claims and liabilities, attempt to convert all of its remaining assets into cash, and make distributions to its stockholders of any remaining cash available for distribution based upon their proportionate ownership at the time of the filing of the certificate of dissolution, subject to applicable legal requirements. Upon the filing of the certificate of dissolution, Histogen intends to cease trading in its common stock, close its stock transfer books and discontinue recording transfers of shares of its capital stock, in accordance with applicable law. Histogen currently expects that its existing capital resources together with the anticipated net proceeds from any sale of pipeline assets will enable it to meet its remaining liabilities and obligations with sufficient reserves. The amount actually distributable, however, may vary substantially from any estimate provided by the company based on a number of factors. Duyuru • Jun 06
Histogen Receives Letter from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(a)(2) On June 5, 2023, Histogen Inc. received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period between April 21, 2023, through June 2, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until December 4, 2023 (the “Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). In order to regain compliance with Nasdaq’s minimum bid price requirement, the Company’s common stock must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during the Compliance Period. In the event the Company does not regain compliance by the end of the Compliance Period, the Company may be eligible for additional time to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split if necessary. If the Company meets these requirements, the Company may be granted an additional 180 calendar days to regain compliance. However, if it appears to Nasdaq that the Company will be unable to cure the deficiency, or if the Company is not otherwise eligible for the additional cure period, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The letter has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on The Nasdaq Capital Market, subject to the Company’s compliance with the other listing requirements of The Nasdaq Capital Market. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other listing criteria of The Nasdaq Capital Market. Duyuru • Jan 04
Histogen Inc. Hires Alfred P. Spada as Chief Scientific Officer Histogen Inc. announced the appointment of Alfred P. Spada Ph.D. as Chief Scientific Officer. Alfred P. Spada, Ph. D. is a seasoned veteran of pharmaceutical discovery and development with over 35 years of combined experience in large Pharma and Biotech. Dr. Spada most recently served as President and CEO of Aya Biosciences focused on the discovery and development of novel therapies for the treatment of severe neuropsychiatric disorders where he identified the company’s orally active clinical candidate and completed necessary IND-enabling studies to position the asset for clinical evaluation. Prior to joining Aya Biosciences, Dr. Spada was co-founder, EVP of R&D and CSO of Conatus Pharmaceuticals until its merger with Histogen in May 2020. At Conatus, Dr. Spada was responsible for the management of all preclinical and safety activities and assisted in the generation of IND packages and presentations to support the company’s clinical assets. Prior to Conatus, Dr. Spada was the VP of Preclinical and Pharmaceutical Development at Idun Pharmaceuticals until its acquisition by Pfizer in 2005 and prior to Idun, the Director of Chemistry in the United States for Rhone-Poulenc Rorer and Aventis Pharmaceuticals. Dr. Spada received his Ph.D. in organic chemistry from MIT and conducted post-doctoral studies at Yale. Dr. Spada holds a BS in chemistry from Worcester Polytechnic Institute. Reported Earnings • May 13
First quarter 2022 earnings released: US$0.013 loss per share (vs US$0.14 loss in 1Q 2021) First quarter 2022 results: US$0.013 loss per share (up from US$0.14 loss in 1Q 2021). Revenue: US$3.76m (up US$3.32m from 1Q 2021). Net loss: US$673.0k (loss narrowed 84% from 1Q 2021). Over the next year, revenue is expected to shrink by 100% compared to a 25% growth forecast for the industry in the US. Price Target Changed • Apr 27
Price target decreased to US$2.25 Down from US$2.70, the current price target is an average from 2 analysts. New target price is 1,013% above last closing price of US$0.20. Stock is down 82% over the past year. The company posted a net loss per share of US$0.39 last year. Reported Earnings • Mar 13
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: US$0.39 loss per share (up from US$2.08 loss in FY 2020). Net loss: US$15.0m (loss narrowed 20% from FY 2020). Products in clinical trials Phase I: 3 Revenue was in line with analyst estimates. Over the next year, revenue is expected to shrink by 100% compared to a 60% growth forecast for the pharmaceuticals industry in the US. Reported Earnings • May 16
First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.55 loss in 1Q 2020) First quarter 2021 results: Net loss: US$4.27m (loss widened 132% from 1Q 2020). Reported Earnings • Mar 16
Full year 2020 earnings released: US$2.08 loss per share (vs US$0.89 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$2.06m (down 82% from FY 2019). Net loss: US$18.8m (loss widened US$15.8m from FY 2019). Products in clinical trials Phase I: 2 Executive Departure • Mar 11
Independent Director has left the company On the 10th of March, Yizhuo Zhang's tenure as Independent Director ended after 4.5 years in the role. As of December 2020, Yizhuo personally held 600.98k shares (US$456k worth at the time). A total of 5 executives have left over the last 12 months. Is New 90 Day High Low • Feb 11
New 90-day high: US$1.72 The company is up 17% from its price of US$1.47 on 12 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 22% over the same period. Is New 90 Day High Low • Dec 18
New 90-day low: US$1.19 The company is down 28% from its price of US$1.65 on 18 September 2020. The American market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 16% over the same period. Is New 90 Day High Low • Dec 01
New 90-day low: US$1.31 The company is down 32% from its price of US$1.92 on 02 September 2020. The American market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 13% over the same period.